Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions

Ignjatović, Dejan; Aasland, Kristine; Pettersen, Marianne; Sund, Ståle; Chen, Yin; Spasojevic, Milan; Nesgaard, Jens Marius

doi:10.1016/j.amjsurg.2009.08.038

Cited by 35 publications

(68 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rats were stratified and randomly placed in different groups (nZ8 per group), receiving, straight after growth plate injury, a single i.p. injection of anti-VEGF antibody (Bevacizumab) (Genentech/Roche, San Francisco, CA, USA) at 2.5 mg/kg (Ignjatovic et al 2010), or saline vehicle control. A group of non-injured rats (nZ8) which did not receive any treatments were killed on day 14 and were used as normal controls.…”

Section: Growth Plate Injury and Treatment Trialmentioning

confidence: 99%

The potential role of VEGF-induced vascularisation in the bony repair of injured growth plate cartilage

Chung¹,

Foster²,

Chen³

2014

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Growth Plate Injury and Treatment Trialmentioning

confidence: 99%

The potential role of VEGF-induced vascularisation in the bony repair of injured growth plate cartilage

Chung¹,

Foster²,

Chen³

2014

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…However, it has proved to be active in rats not only in tumor xenograft models but also in several other models, e.g. in the prevention of intraperitoneal adhesion after its intraperitoneal administration in rats [38] or in many ophthalmologic rat models, where it was reported to decrease neovascularization of the rat cornea, for example [17,18,19,20,21]. …”

Section: Discussionmentioning

confidence: 99%

“…Finally, the effectiveness of bevacizumab in a rat model has been reflected by decreased intraperitoneal adhesion following a single intraoperative dose of 2.5 mg/kg of body weight i.p. [38]. …”

Section: Discussionmentioning

confidence: 99%

Intraperitoneal Administration of Bevacizumab Intraoperatively Does Not Affect Abdominal Wound Healing in Rats

Pavlidis

Ballas²,

Psarras³

et al. 2011

Eur Surg Res

View full text Add to dashboard Cite

Background: Bevacizumab is a monoclonal antibody targeted at vascular endothelial growth factor (VEGF) to treat advanced colorectal cancer as well as other malignancies, but the ideal time point for its administration in patients scheduled for surgery is not well defined due to serious concerns regarding possible side effects on wound healing. Therefore, we conducted an experimental study in rats to clarify this issue. Methods: Four groups of 10 Wistar rats each underwent a 4-cm midline laparotomy and closure of the wound in 2 layers. In the treatment groups (A and B), bevacizumab (Avastin®) received a single dose of 5 mg/kg i.p., and an equal amount of saline was given to the control groups (C and D). Groups A and C were sacrificed on the 7th postoperative day, and groups B and D on the 14th postoperative day. Wounds were inspected by two independent observers upon sacrifice and results were recorded; wound tissues were sent for histology to assess the degree of fibrosis and measurement of tissue hydroxyproline levels. Serum levels of endothelin-1, C-reactive protein, pro-oxidant/antioxidant balance and carbonylated proteins were also determined. For statistical analysis, the Mann-Whitney U test was used. Results: Wound healing did not differ among groups both on the 7th and the 14th postoperative days, and there was also no significant difference regarding the degree of inflammation, fibroblast proliferation and collagen synthesis, as well as hydroxyproline and biochemical marker levels among the groups. Conclusions: Intraperitoneal bevacizumab administered intraoperatively does not significantly affect abdominal wound healing in rats.

show abstract

“…Adhensive SBO is a major cause of morbidity and financial expenditure in hospitals. Lots of studies have been performed to yield a method of preventing postoperative adhesions [2,3]. However, there is no proven method to prevent formation of adhesions postoperatively.…”

Section: Introductionmentioning

confidence: 99%

“…The etiologies of SBO include the following: (1) endoluminal obstruction (biliary ileus, phytobezoard, foreign body, etc. ), (2) intrinsic lesions (Crohn's disease, lymphoma, etc. ), (3) extrinsic obstruction (adhesions, hernia, carcinomatosis, etc.…”

Section: Introductionmentioning

confidence: 99%

Predictive Factors for Surgical Intervention in Patients over the Age of 80 with Adhensive Small-Bowel Obstruction

Lou

Yan

Hu³

et al. 2015

Indian J Surg

View full text Add to dashboard Cite

Adhensive small-bowel obstruction (SBO) remains a common cause of admission to surgical wards around the world. Given the growing elderly population, the number of elderly patients with adhensive SBO can be expected to increase substantially. Timely and appropriate treatment would improve morbidity and mortality rates in elderly patients with adhensive SBO. However, accurately determining which patients should undergo surgical treatment during the hospitalization remains difficult. The aim of this study was to identify predictive factors for surgical intervention in patients aged over 80 years presenting with SBO due to postoperative adhesions. A clinical and radiological data for the assessment of patients presenting with adhensive SBO were collected. A logistic regression model was applied to identify risk factors that would predict the need of surgical intervention. A total of 21 patients (13 males, 8 females) were treated during a 3.5-year period. The mean age was 85.5±4.7 years, ranging from 80 to 97 years. There is no significant difference in age (group 1 87.6±5.9 years vs. group 2 84.8±4.3 years, p=0.262) between two groups. Serious coexisting diseases were noted in 13 (61.9 %, 13/21) patients. Primary hypertension, cardiac diseases, and diabetes mellitus were common coexisting conditions. However, there is no significant difference in comorbidities (40 vs. 68.8 %, p=0.325) between group 1 and group 2. Adhensive SBO was successfully treated with conservative treatment in 16 patients (76.2 %, 16/21, group 2), whereas conservative treatment failed in 5 patients (23.8 %, 5/21, group 1), who subsequently underwent laparotomy. Postoperative complication rate was 14.3 % (wound infection, 1/5) and mortality was 0 % (0/5) in group 1. One patient death was recorded in group 2 (1/16, 6.3 %). The overall mean hospital stay was 10.0±5.9 days (range 3-27 days). Group 1 had a longer hospital stay than group 2. However, the difference did not reach the significant level (12.8±8.2 vs. 9.1±5.9 days, p=0.274). On univariate analysis, the need for surgical intervention was significantly associated with granulocyte percentage (2.768, 0.961-7.975, p= 0.059), CT findings of free intraabdominal fluid (28.000, 1.988-394.405, p=0.014), and level of albumin (0.265, 0.073-0.970, p=0.045). On multivariate analysis, the predictive factor was free intraabdominal fluid (28.000, 1.988-394.405, p=0.014). Conservative treatment remains a major consideration in patients over the age of 80. Although major cases of adhensive SBO are successfully treated with conservative methods, some fail to respond, and the independent risk factor for surgical indication is free intraabdominal fluid.Zheng Lou and Fei-hu Yan contributed equally to this work.* En-da Yu

show abstract

Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions

Cited by 35 publications

References 18 publications

The potential role of VEGF-induced vascularisation in the bony repair of injured growth plate cartilage

The potential role of VEGF-induced vascularisation in the bony repair of injured growth plate cartilage

Intraperitoneal Administration of Bevacizumab Intraoperatively Does Not Affect Abdominal Wound Healing in Rats

Predictive Factors for Surgical Intervention in Patients over the Age of 80 with Adhensive Small-Bowel Obstruction

Contact Info

Product

Resources

About